Premium
Prognostic impact of non‐urothelial carcinoma of the upper urinary tract: Analysis of hospital‐based cancer registry data in Japan
Author(s) -
Nagumo Yoshiyuki,
Kawai Koji,
Kojima Takahiro,
Shiga Masanobu,
Kojo Kosuke,
Tanaka Ken,
Kandori Shuya,
Kimura Tomokazu,
Kawahara Takashi,
Okuyama Ayako,
Higashi Takahiro,
Nishiyama Hiroyuki
Publication year - 2021
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.14393
Subject(s) - medicine , stage (stratigraphy) , urothelial carcinoma , carcinoma , urology , proportional hazards model , upper urinary tract , oncology , t stage , cancer , adenocarcinoma , urinary system , ureter , bladder cancer , paleontology , biology
Objectives To identify the prognosis of patients with non‐urothelial carcinoma of the upper urinary tract and compare it with that of patients with urothelial carcinoma. Methods We used hospital‐based cancer registry data in Japan to extract histologically confirmed non‐urothelial carcinoma and urothelial carcinoma cases of the upper urinary tract diagnosed in 2008–2009. We estimated the 5‐year overall survival by a Kaplan–Meier analysis. The Cox proportional hazards regression analysis was used to evaluate prognostic factors. Results A total of 2567 upper urinary tract cancer patients with confirmed histological subtypes were identified. The most common histology of non‐urothelial carcinoma was squamous cell carcinoma ( n = 88, 3.4%) followed by adenocarcinoma ( n = 33, 1.3%) and small cell carcinoma ( n = 10, 0.4%). The proportion of advanced stage in the squamous cell carcinoma patients was significantly higher than that in the urothelial carcinoma patients ( P = 0.003). In stage IV, the proportion of patients who received a combination of surgery + chemotherapy in the urothelial carcinoma group was higher than that in the non‐urothelial carcinoma group (34% vs 16%, respectively). The 5‐year overall survival rates of the non‐urothelial carcinoma patients at stages I–III and stage IV were significantly worse than those of the urothelial carcinoma patients ( P = 0.003, P < 0.001, respectively). In multivariate analyses, age ≥73 years, advanced stage (stage IV), tumor location (ureter) and the presence of non‐urothelial carcinoma histology were independent poor prognosis factors. Conclusion The prognosis of non‐urothelial carcinoma patients is worse than that of urothelial carcinoma patients, especially for non‐urothelial carcinoma patients at stage IV. More effective systemic therapies are required to improve these patients’ oncological outcomes.